ZLDPF (Zealand Pharma AS) Purchase Of Investment : $-1,682.38 Mil (TTM As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma AS Purchase Of Investment?

Zealand Pharma AS's purchase of investment for the three months ended in Dec. 2024 was $-252.23 Mil. It means Zealand Pharma AS spent $252.23 Mil on purchasing investments. Zealand Pharma AS's purchase of investment for the trailing twelve months (TTM) ended in Dec. 2024 was $-1,682.38 Mil.

Compared with last quarter ($-1,092.76 Mil in Sep. 2024 ), Zealand Pharma AS spent less money on purchasing investments in Dec. 2024 ($-252.23 Mil).

Zealand Pharma AS Purchase Of Investment Historical Data

The historical data trend for Zealand Pharma AS's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Purchase Of Investment Chart

Zealand Pharma AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Purchase Of Investment

Get a 7-Day Free Trial

-99.74

-316.01

-1,608.75

Zealand Pharma AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Purchase Of Investment	Get a 7-Day Free Trial															-60.27	-260.18	-77.20	-1,092.76	-252.23

Zealand Pharma AS Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,682.38 Mil.

Zealand Pharma AS Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (OTCPK:ZLDPF) » Definitions » Purchase Of Investment

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.